SCYNEXIS Future Growth
Future criteria checks 0/6
SCYNEXIS's revenue and earnings are forecast to decline at 13% and 23.3% per annum respectively while EPS is expected to decline by 25.2% per annum.
Key information
-23.3%
Earnings growth rate
-25.2%
EPS growth rate
Pharmaceuticals earnings growth | 21.4% |
Revenue growth rate | -13.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 31 Jan 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Apr 13Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)
Mar 15Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like
Feb 01Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval
Jan 06Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares
Dec 28Scynexis shares drop after pricing its equity offering
Dec 17SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?
Dec 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 111 | 64 | 23 | 33 | 5 |
12/31/2025 | 90 | 38 | 112 | 118 | 5 |
12/31/2024 | 71 | 25 | N/A | 55 | 5 |
12/31/2023 | 142 | 84 | N/A | 78 | 4 |
9/30/2023 | 136 | 72 | 45 | 45 | N/A |
6/30/2023 | 136 | 44 | 10 | 10 | N/A |
3/31/2023 | 6 | -91 | -83 | -83 | N/A |
12/31/2022 | 5 | -63 | -80 | -80 | N/A |
9/30/2022 | 4 | -78 | -83 | -83 | N/A |
6/30/2022 | 3 | -49 | -78 | -77 | N/A |
3/31/2022 | 2 | -34 | -71 | -70 | N/A |
12/31/2021 | 13 | -33 | -56 | -55 | N/A |
9/30/2021 | 13 | -46 | -46 | -46 | N/A |
6/30/2021 | 12 | -45 | -39 | -39 | N/A |
3/31/2021 | 12 | -53 | -36 | -36 | N/A |
12/31/2020 | N/A | -55 | -49 | -49 | N/A |
9/30/2020 | N/A | -27 | -46 | -46 | N/A |
6/30/2020 | N/A | -36 | -47 | -47 | N/A |
3/31/2020 | 0 | -38 | -46 | -46 | N/A |
12/31/2019 | 0 | -54 | -38 | -38 | N/A |
9/30/2019 | 0 | -37 | -31 | -31 | N/A |
6/30/2019 | 0 | -29 | -27 | -26 | N/A |
3/31/2019 | 0 | -31 | -27 | -27 | N/A |
12/31/2018 | 0 | -12 | -29 | -28 | N/A |
9/30/2018 | 0 | -22 | -28 | -27 | N/A |
6/30/2018 | 0 | -31 | -27 | -27 | N/A |
3/31/2018 | 0 | -24 | -26 | -26 | N/A |
12/31/2017 | 0 | -25 | -25 | -25 | N/A |
9/30/2017 | 0 | -21 | -24 | -24 | N/A |
6/30/2017 | 0 | -24 | N/A | -26 | N/A |
3/31/2017 | 0 | -28 | N/A | -27 | N/A |
12/31/2016 | 0 | -30 | N/A | -29 | N/A |
9/30/2016 | 0 | -35 | N/A | -31 | N/A |
6/30/2016 | 0 | -31 | N/A | -30 | N/A |
3/31/2016 | 0 | -30 | N/A | -29 | N/A |
12/31/2015 | 0 | -28 | N/A | -25 | N/A |
9/30/2015 | 1 | -23 | N/A | -20 | N/A |
6/30/2015 | 1 | -19 | N/A | -18 | N/A |
3/31/2015 | 1 | -11 | N/A | -14 | N/A |
12/31/2014 | 1 | -7 | N/A | -9 | N/A |
9/30/2014 | 4 | -42 | N/A | -9 | N/A |
6/30/2014 | 8 | -43 | N/A | -6 | N/A |
3/31/2014 | 12 | -47 | N/A | -2 | N/A |
12/31/2013 | 17 | -47 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCYX's earnings are forecast to decline over the next 3 years (-23.3% per year).
Earnings vs Market: SCYX's earnings are forecast to decline over the next 3 years (-23.3% per year).
High Growth Earnings: SCYX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SCYX's revenue is expected to decline over the next 3 years (-13% per year).
High Growth Revenue: SCYX's revenue is forecast to decline over the next 3 years (-13% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCYX's Return on Equity is forecast to be high in 3 years time